Sep. 12 at 11:06 AM
$DTIL
Precision BioSciences Presents Data from the Phase 1 E
09/12/2025 - 01:01 PM
DURHAM, N.C.--(BUSINESS WIRE)-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that the Company presented clinical data from the Phase 1 ELIMINATE-B trial of PBGENE-HBV in patients with chronic Hepatitis B. The data was presented at the International Coalition to Eliminate HBV (ICE-HBV) “HBV Cure Symposium” Meeting in Berlin, Germany, on September 12th.
“We are excited to present the progress for the ELIMINATE-B trial with the HBV community at this year’s ICE-HBV symposium following our data update on August 6th,” said Cassie Gorsuch, PhD, Chief Scientific Officer at Precision BioSciences
https://www.stocktitan.net/news/DTIL/precision-bio-sciences-presents-data-from-the-phase-1-eliminate-b-542do9bbxkzl.html